77
Participants
Start Date
July 31, 2010
Primary Completion Date
March 31, 2015
Study Completion Date
August 31, 2016
Ofatumumab
IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
South Carolina Oncology Associates, Columbia
Northeast Georgia Medical Center, Gainesville
Woodlands Medical Specialists, Pensacola
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
The Ohio State University, Columbus
Oncology Hematology Care, Cincinnati
Providence Medical Group, Terre Haute
St. Louis Cancer Care, Chesterfield
Los Robles, Thousand Oaks
Portsmouth Regional Hospital, Portsmouth
Hematology-Oncology Associates of Northern NJ, Morristown
Collaborators (1)
GlaxoSmithKline
INDUSTRY
SCRI Development Innovations, LLC
OTHER